{"entity":{"id":"nct06949111","kind":"trial","name":"Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）","aka":[],"tldr":"A phase 2 trial of cAPOX (capecitabine, oxaliplatin) and capecitabine in colorectal cancer, run by Hebei Medical University Fourth Hospital, now recruiting.","summary":"Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color） is a phase 2, randomised interventional study registered as NCT06949111 by Hebei Medical University Fourth Hospital, with a registry enrolment figure of 128 participants, started 2025-05-15 and due to reach its primary completion in 2028-05-30. Interventions recorded: radiotherapy; CAPOX; Capecitabine; Iparomlimab and Tuvonralimab Injection. Conditions listed: Colon Cancer. Primary outcome: Tumor Complete Response (CR) Rate. Colorectal eligibility wording from the registry: \"Histopathologically confirmed diagnosis of colon adenocarcinoma (including mucinous adenocarcinoma), identified as pMMR/MSS type; the primary tumor site must be specified (left colon defined as from the splenic flexure to the rectosigmoid junction, right colon defined as from the cecum to the proxim\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06949111","url":"https://clinicaltrials.gov/study/NCT06949111"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["colon-cancer"],"sections":[],"technologies":["cytotoxic-chemotherapy","imrt-igrt","platinum"],"targets":[],"drugs":["capox","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06949111","phase":"2","setting":"Efficacy and Safety of Conversion Therapy for pMMR/MSS T4M0 Colon Cancer Patients Treated With Radiotherapy and Systemic Therapy: a Prospective, Open-label, Multi-center, Randomized Controlled Trial（Neo-Color）","sponsor":"Hebei Medical University Fourth Hospital","enrolled":128,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06949111/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"capox","kind":"drug","name":"CAPOX (capecitabine, oxaliplatin)","route":"/drugs/capox/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}